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Galactocerebrosidase (GALC, EC 3.2.1.46) is a lysosomal
hydrolase that degrades galactosylceramide, a lipid compo-
nent of myelin, and its deficiency results in demyelination.
The resulting disease, known as globoid cell leukodystrophy
(GLD) or Krabbe disease, affects the CNS and is inherited in
an autosomal recessive manner (Wenger et al. 2000).
Galactosylceramide is found mostly in the brain, particularly
in myelin sheaths. Unmetabolized galactosylceramide does
accumulate in macrophages, which form characteristic
globoid cells. Galactosylceramide is unique among the
sphingolipids in its ability to elicit globoid cells (Suzuki
1985). Another substrate of GALC, psychosine (galactos-
ylsphingosine), accumulates in neural tissues. The psycho-
sine metabolism is impaired in patients with Krabbe disease
and the brains of patients affected with this disease may
contain 10–100 times the normal amount of psychosine
(Suzuki 1998). Psychosine is highly cytotoxic primarily
affecting oligodendrocytes, the myelin forming cells and
causing their apoptotic death (Taniike et al. 1999; Zaka and
Wenger 2004). Human GALC has been purified from urine
and lymphocytes (Chen and Wenger 1993; Sakai et al.
1994a) and its cDNA and genomic sequences have been
determined (Chen et al. 1993; Sakai et al. 1994b; Luzi et al.
1995). GALC cDNA sequences from other species including
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Abstract
A number of studies have shown that a short peptide, the
protein transduction domain (PTD) derived from the HIV-1 Tat
protein (Tat-PTD) improved cellular uptake in vitro and dis-
tribution in vivo of recombinant proteins bearing such PTDs
when administered systemically. To investigate the effects of
Tat-PTD addition on the subcellular localization of the lyso-
somal enzyme galactocerebrosidase (GALC, EC 3.2.2.46)
and with a view towards designing improved therapeutic
strategies for Krabbe disease (globoid cell leukodystrophy),
mouse GALC was tagged C-terminally with the Tat-PTD.
Compared with unmodified GALC, GALC bearing a Tat-PTD,
a myc epitope and 6 consecutive His residues [GALC-TMH
(Tat-PTD, a myc epitope and 6 consecutive His residues)]
was found to be secreted more efficiently. Also, GALC-TMH
was found to be taken up by cells both via mannose-6-phos-
phate receptor (M6PR)-mediated endocytosis as well as by
M6PR-independent mechanisms. GALC-TMH displayed in-
creased M6PR-independent uptake in fibroblasts derived from
twitcher mice (a murine model of globoid cell leukodystrophy)
and in neurons derived from the mouse brain cortex com-
pared with GALC lacking a Tat-PTD. Immunocytochemical
analyses revealed that Tat-modified GALC protein co-local-
ized in part with the lysosome-associated membrane protein-
1. Complete correction of galactosylceramide accumulation
was achieved in twitcher mouse fibroblasts lacking GALC
activity following addition of GALC-TMH. Therefore, GALC-
TMH not only maintained the features of the native GALC
protein including enzymatic function, intracellular transport
and location, but also displayed more efficient cellular uptake.
Keywords: galactocerebrosidase, globoid cell leukodystro-
phy, lentiviral vectors, protein transduction, Tat protein
transduction domain, twitcher mouse model.
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mice, dogs, and rhesus monkeys have also been characterized
(Sakai et al. 1996; Luzi et al. 1997). The human GALC
cDNA codes for 669 amino acids including a 26 amino acid
leader peptide. This correlates with an estimated molecular
mass of 80 kDa of the purified enzyme (Chen and Wenger
1993). The 80-kDa version of human GALC has been found
to undergo proteolysis, resulting in 30- and 50-kDa frag-
ments in the extracellular medium (Nagano et al. 1998).
Over 60 disease-causing mutations have been character-
ized in human patients with Krabbe disease (Wenger et al.
2000). A mutation causing GLD in mice has also been
identified (Wenger 2000). These mice are referred to as
twitcher mice. Twitcher mice are the most widely used
animal model of Krabbe disease to date.
A potential treatment option for Krabbe disease may
involve supplying sufficient GALC activity to still function-
ing oligodendrocytes by enzyme replacement therapy (ERT)
or using gene therapy-based approaches to degrade the
psychosine that is starting to accumulate (Wenger et al.
2000; Lee et al. 2005b). A problem for treating GLD, and
other lysosomal storage diseases (LSDs), is that virtually all
cells in an organism are affected. Clearly, it is not feasible to
correct all cells using gene-based approaches. Fortunately,
however, this is not necessary when cross-correction can
occur. It has been demonstrated that several lysosomal
enzymes, including GALC can be secreted by cells produc-
ing the enzyme and taken up by other cells via the mannose-
6-phosphate receptor (M6PR) (Kornfeld 1987; Nagano et al.
1998). For example, GALC released from GALC-over-
expressing cells was shown to be taken up by fibroblasts
(FBs) derived from Krabbe patients (Rafi et al. 1996) or by
twicher mouse-derived glial cells (Luddi et al. 2001). In
principle, a limited number of overproducing cells should be
able to provide sufficient enzyme to the rest of the organism.
However, the delivery of therapeutic proteins into tissues and
across the blood–brain barrier can be limited due their size
and their biochemical properties. Schwarze et al. (1999)
described the successful uptake of functional Escherichia
coli b-galactosidase fused to a short cationic peptide derived
from the HIV-1 Tat protein through the blood–brain barrier
involving a mechanism known as protein transduction
(Schwarze and Dowdy 2000). In subsequent studies, Xia
et al. (2001), Elliger et al. (2002), and Orii et al. (2005)
tested how the Tat protein transduction domain (PTD)
affected secretion, uptake and biodistribution of b-glucuron-
idase (GUS), the enzyme that is defective in mucopolysac-
charidosis type VII (MPS VII). The Tat motif allowed for
M6PR-independent uptake of the enzyme in vitro and
significantly increased the distribution of GUS secreted from
transduced cells after intravenous or direct brain injection of
recombinant adenovirus vectors encoding GUS tagged with
the Tat-PTD (Xia et al. 2001; Elliger et al. 2002). Improved
intracellular delivery of glucocerebrosidase (the enzyme that
is defective in Gaucher disease) mediated by the HIV-1
Tat-PTD was also observed (Lee et al. 2005a). Thus,
enzymes modified to contain protein transduction motifs
may represent a general strategy for improving the distribu-
tion of secreted proteins following in vivo gene transfer.
The optimal pH for GALC is around 4.2 (Sakai et al.
1994a), a feature that strengthens the feasibility of applying
Tat-PTD-modification to GALC as PTD-mediated uptake is
into endosomes with reduced pH. At least a portion of Tat-
PTD-modified GALC in endosomes is expected to proceed
to lysosomes.
With a view towards establishing improved therapeutic
strategies for GLD, we analyzed in this report the impacts of
a Tat-PTD on enzymatic function, cellular uptake and
intracellular location of mouse GALC.
Experimental procedures
Cell culture
Human embryonic kidney 293 (CRL-1573) and 293T (CRL-11268)
cells, African green monkey COS-7 cells (CRL-1651), and HeLa
cells (CCL-2) were obtained from the American Type Culture
Collection (Manassas, VA, USA). Cells were maintained in
Dulbecco’s modified Eagle’s medium (Invitrogen–Gibco, Gaithers-
burg, MD, USA) with 10% heat inactivated fetal bovine serum
(Hyclone, Logan, UT, USA), 2.5 mmol/L L-glutamine, 100 units/
mL penicillin, and 100 lg/mL streptomycin (all from Invitrogen–
Gibco). Primary cultures of mouse skin FBs were established from
4-week-old B6.CE-Galctwi twitcher mice (The Jackson Laboratory,
Bar Harbor, ME, USA) and from wild-type mice. The genotypes of
animals were determined by PCR analysis using tail DNA isolated
from 1-week-old mice as described (Sakai et al. 1996). Skin FBs
were maintained in Dulbecco’s modified Eagle’s medium with 15%
heat inactivated fetal bovine serum, 2.5 mmol/L L-glutamine,
100 units/mL penicillin, and 100 lg/mL streptomycin. Mouse brain
cortex neurons (M-CX-300; Cambrex Bio Science Walkersville,
Inc., Walkersville, MD, USA) were plated on plates coated with
poly-D-lysine and laminin and maintained in neurobasal medium
containing 2% B27 supplement, 2 mmol/L L-glutamine, 100 units/
mL penicillin, and 100 lg/mL streptomycin (Invitrogen–Gibco).
GALC expression constructs
The lentiviral plasmid pNL-GALC-IRES-Neo containing a mouse
GALC cDNA sequence (Sakai et al. 1996), driven by the human
cytomegalovirus (CMV)-IE promoter was constructed by inserting a
2.3 kb SmaI–BamHI fragment derived from pSVL/MGal (kindly
provided by Norio Sakai, Osaka University) into pNL-IRES-Neo cut
with EcoRI and BamHI. pNL-IRES-Neo was derived from pNL-
Neo (Mochizuki et al. 1998) by substituting the Neo sequence with
an IRES-Neo fragment derived from pIRES1-Neo (Clontech, Palo
Alto, CA, USA). To construct pNL-GALC-MH/CMV, a 1.1-kb
mouse GALC cDNA fragment was generated by PCR, using a
forward primer (5¢-GACAGCGGGCCATCTAGAGAA-3¢) and a
reverse primer (5¢-TTGTTCGAAGGGCCCGCGAGCAGCTTC-
CACGCGAAA-3¢). This 1.1-kb fragment encodes the C-terminal
part of the mouse GALC protein (amino acids 348–668) and also
contains a GGG codon replacing the TAG stop codon. The fragment
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was cloned into the XbaI/ApaI sites of pcDNA3.1/myc-His (Invitro-
gen, Carlsbad, CA, USA) resulting in pcDNA-GALC(FC)MH
encoding GALC with in-frame myc epitope and His tag sequences.
A 1.2-kb XbaI fragment containing the 5¢ part of the GALC cDNA
(encoding amino acids 1–347) from pLITMUS-GALC (generated by
cloning the GALC cDNA into the NcoI/BamHI sites of pLITMUS
29, New England Biolabs, Beverly, MA, USA) was then inserted into
the XbaI site of pcDNA-GALC(FC)MH to generate pcDNA-GALC-
MH. Finally, the SnaBI/PmeI fragment derived from pcDNA-
GALC-MH was cloned into the SnaBI/XhoI sites of pNL-EGFP/
CMV (Reiser et al. 2000) resulting in pNL-GALC-MH/CMV. To
generate pcDNA-GALCDMH, a 2.1-kb KpnI/FspI fragment from
pLITMUS-GALC was cloned into the KpnI/XbaI sites of pcDNA3.1/
myc-His. To construct pNL-GALC-TMH/CMV, the pcDNA3.1/Tat-
myc-His plasmid was modified by replacing the pcDNA3.1/myc-
His-derived myc-His epitope-encoding sequence with a sequence
encoding a HIV-1 Tat-PTD. This sequence consisted of a 104-bp
oligonucleotide encoding the HIV-1 TAT-PTD (YGRKKR-
RERRRG) (Green and Loewenstein 1988) in frame with a myc-
His epitope sequence. The primers used in the overlap extension




fragment with an ApaI site at the 5¢-end and an AgeI site at 3¢-end
was cloned into the ApaI/AgeI sites of pcDNA3.1/myc-His, resulting
in pcDNA3.1/Tat-myc-His. Next, the XbaI/ApaI fragment from
pcDNA-GALC-MH was cloned into the XbaI/ApaI sites of
pcDNA3.1/Tat-myc-His resulting in pcDNA-GALC(FC)TMH.
Finally, the SnaBI/PmeI fragment derived from pcDNA-
GALC(FC)TMH was cloned into the SnaBI/XhoI sites of pNL-
EGFP/CMV, resulting in pNL-GALC-TMH/CMV.
Test of recombinant GALC proteins by transient transfection
293T cells were subjected to transient transfection as described
(Reiser et al. 1996). Plasmid pNL-LacZ(co) (Kuroda and Reiser,
unpublished) encoding E. coli b-galactosidase was co-transfected to
monitor transfection efficiencies. b-galactosidase activity was
determined as described by Bao et al. (2004).
Lentiviral vector production and transduction of cells
Lentivirus vector stocks were prepared as described previously
(Reiser 2000). Virus titers and vector copies in transduced cells were
determined by real-time PCR using primers and probes specific for
the HIV-1 group-specific antigen (Gag)coding region (Zhang et al.
2004). Target cells were transduced with lentiviral vectors using
multiplicities of infection of 30.
Western blot analysis
Cell culture supernatant aliquots (200 lg) from 293T and Hela cells
transduced with GALC-encoding lentiviral vectors were collected
by centrifugation and concentrated using StrataClean Resin (Strat-
agene, La Jolla, CA, USA). Concentrated proteins were subjected to
sodium dodecyl sulfate–polyacrylamide gel electrophoresis using 4–
12% NuPAGE Bis–Tris gels (Invitrogen) and then blotted onto a
polyvinylidene difluoride membrane (Millipore, Bedford, MA,
USA). The membrane was blocked with 3% non-fat milk in Tris
buffered saline with Tween 20, TBST (Sigma-Aldrich, St. Louis,
MO, USA) buffer, and incubated with a monoclonal anti-myc
antibody (Invitrogen) followed by alkaline phosphatase conjugated
goat anti-mouse IgG (Bio-Rad, Hercules, CA, USA). Blots were
treated using the Lumi-Phos WB reagent (Pierce Biotechnology
Inc., Rockford, IL, USA) and then exposed to X-ray films.
GALC assay
Cultured cells were harvested from tissue culture plates using a cell
lifter and washed twice with phosphate-buffered saline (PBS). Cell
pellets were re-suspended and homogenized in H2O containing
1 mmol/L phenylmethylsulfonyl fluoride (Sigma–Aldrich) at 4C.
Cell extracts were centrifuged (22 088 g for 15 min, 4C). Protein
concentrations were determined using the bicinchoninic acid protein
assay kit (Pierce). GALC activity was determined using 3H-
galactosylceramide (American Radiolabeled Chemicals, St Louis,
MO, USA) as a substrate as described by Raghavan and Krusell
(1986). Twenty micrograms of cell extract or 50 lL of cell culture
supernatant from lentivirus-transduced cells were used for the assay.
GALC units are defined as nmoles of 3H-galactosylceramide
hydrolyzed per hour.
Determination of GALC uptake
For GALC production, COS-7 cells were transduced with lentiviral
vectors encoding GALC-MH or GALC-TMH for 22 h in the
presence of 8 lg/mL polybrene (Sigma–Aldrich). Tranduced cells
were passaged twice and cell culture supernatants were collected. To
determine GALC uptake, 4 mL of conditioned media containing
GALC-MH or GALC-TMH (60–120 GALC units) were added to
4 · 105 untransduced cells including 293T cells, COS-7 cells or
twitcher mouse FBs (Twi FBs) in the presence or absence of
5 mmol/L M6P (Sigma–Aldrich). For GALC uptake by mouse brain
cortex neurons, GALC-MH or GALC-TMH (90 GALC units) were
added in the presence or absence of 5 mmol/L M6P. Twenty-four
hours later, the cells were washed with PBS and harvested, and cell
extracts prepared and GALC activities determined.
Immunofluorescence labeling and microscopy
To assess the subcellular distribution of the GALC-TMH protein,
transduced Twi FBs were plated on coverslips in six-well plates,
fixed using 3% paraformaldehyde in PBS for 20 min and blocked
with PBS containing 10% goat serum and 0.05% saponin (both from
Sigma–Aldrich) for 1 h. The coverslips were incubated with mouse
monoclonal anti-myc (Invitrogen; 1 : 250 dilution) or rat mono-
clonal anti-mouse lysosomal-associated protein-1 (Lamp-1) (BD
Biosciences, Bedford; 1 : 250), diluted in phosphate buffered saline
with 0.05% Tween 20 (PBST) containing 1% bovine serum albumin
(BSA) and 0.05% saponin for 2 h at 25C followed by three 10-min
washes with PBST. Alexa 488-conjugated goat anti-mouse-IgG or
Alexa 568-conjugated goat anti-rat-IgG (Molecular Probes, Eugene,
OR, USA; 1 : 1500 dilution) were then applied and the cells
incubated for 1 h at 25C followed by three 10-min washes with
PBST. The coverslips were mounted with ProLong Gold anti-fade
reagent with 4¢-6-Diamidino-2-phenylindole (Molecular Probes).
Images were taken using a Bio-Radiance 2100 scanning confocal
microscope (Bio-Rad).
To analyze uptake of GALC-TMH by Twi FBs, 2 mL of
conditioned medium containing GALC-TMH (43 GALC units)
were added to 2 · 104 Twi FBs plated on coverslips in six-well
 2007 The Authors
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plates. Twenty-eight hours later, cells were fixed using 3%
paraformaldehyde in PBS for 20 min and blocked with PBS
containing 10% goat serum and 0.05% saponin for 1 h. The
coverslips were incubated with affinity-purified rabbit anti-GALC
polyclonal antibodies (CL1475 1 : 800) (Lee et al. 2005b, 2007) or
rat monoclonal anti-mouse Lamp-1 (BD Biosciences; 1 : 500), for
2 h at 25C followed by three washes with PBST. Alexa 488-
conjugated goat anti-rabbit-IgG (1 : 500 dilution) or Alexa 568-
conjugated goat anti-rat-IgG (1 : 1000 dilution) were then applied
and the cells incubated for 2 h at 25C followed by three 10-min
washes with PBST.
Analysis of cells using fluorescent lipids
Twi FBs, wild-type FBs or lentiviral vector NL-GALC-TMH/CMV-
transduced FBs plated on Cell-Tak adhesive-treated coverslips (BD
Biosciences) were incubated with a solution containing BODIPY-
FLC12-galactoceramide (BODIPY-GalCer; Molecular Probes) and
BSA (5 lmol/L each in Hanks’-buffered salt solution, containing
10 mmol/L HEPES, pH 7.4; Hanks’ balanced salt solution (HBSS)/
HEPES) for 45 min at 37C. Cells were washed twice with HBSS/
HEPES and incubated with fresh medium for 1 h at 37C, followed
by a ‘back-exchange’ with 5% BSA (fatty acid free, Sigma–Aldrich)
in HBSS/HEPES at 10C (Martin and Pagano 1994). The coverslips
were rinsed with PBS and mounted with ProLong Gold anti-fade
reagent. Images were taken using an Olympus TH 4–100 inverted
fluorescence microscope. Similar analyses were conducted using
Twi FBs incubated with conditioned medium collected from 293
cells stably expressing GALC-TMH for 24 h before applying
BODIPY-GalCer.
Results
C-terminal addition of a Tat-PTD does not impair GALC
activity
To distinguish recombinant mouse GALC from endogenous
GALC and to assess the effects of the Tat-PTD on the
activity of recombinant GALC, a number of different GALC
expression constructs were prepared. These constructs
encoded 24 additional amino acids at the C-terminus of the
GALC protein including a myc epitope sequence and six
consecutive His residues. Another construct encoded an
eleven amino acid PTD derived from the HIV-1 Tat protein
(Green and Loewenstein 1988; Schwarze and Dowdy 2000)
in addition to the myc epitope sequence and the six His
residues (Fig. 1a). The corresponding GALC proteins are
referred to as GALC-MH and GALC-TMH, respectively.
The results presented in Fig. 1b show that the specific
activity of the GALC-MH enzyme in total cell extracts was
similar to that of the unmodified (untagged) recombinant
GALC enzyme following transient transfection of 293T cells
using GALC and GALC-MH-encoding plasmids. However,
the specific activity of GALC fused to the Tat-PTD was
reduced by about 37% relative to that of GALC-MH (Fig. 1b).
A similar reduction in GALC-TMH activity relative to
GALC-MH (about 40%) was observed when GALC levels
were normalized based on b-galactosidase expression follow-
ing co-transfection using the pNL-LacZ(co) plasmid (data not
shown). Also, a GALC expression construct with the last 11
amino acid residues of GALC deleted (GALCD-MH) lacked
enzymatic activity altogether (Fig. 1b). This indicates that the
mouse GALC protein can tolerate C-terminal extensions and
that a full-length GALC C-terminus is critical for GALC
activity.
Impact of the Tat-PTD on the release of GALC into the
extracellular medium
To assess the impact of the Tat-PTD on the release of
recombinant GALC into the extracellular medium, lentiv-
iral vectors encoding GALC-MH and GALC-TMH were
generated. The GALC activity in transduced African green
(b)
(a)
Fig. 1 Design and functional analysis of galactocerebrosidase
(GALC) expression constructs. (a) Expression constructs. GALC:
unmodified GALC protein; GALC-MH: GALC fusion protein containing
a C-terminal myc-tag and six His residues; GALCD-MH: GALC fusion
protein containing a C-terminal myc-tag (EQKLISEEDL) and six His
residues with the last 11 amino acids at the C-terminus of GALC de-
leted; GALC-TMH: GALC fusion protein containing a C-terminal Tat-
PTD (YGRKKRRQRRR), a myc-tag and six His residues. (b) Specific
activities of recombinant GALC proteins. 293T cells were transiently
transfected with plasmids encoding unmodified GALC, GALC-MH,
GALCD-MH, or GALC-TMH. Cell extracts were prepared 3 days later
and GALC-specific activities (GALC units per mg of cell extract)
determined. Control: extracts from untransfected 293T cells. Data
shown are from three independent experiments and expressed as
mean values ± SD.
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monkey kidney-derived COS-7 cells is shown in Table 1.
A higher proportion of the enzyme activity was found in
the extracellular medium of GALC-TMH-transduced cells
(72.5 ± 3.7%) compared with GALC-MH-transduced cells
(58.8 ± 8.3%) (Table 1). These results indicate that fusion
of Tat-PTD with the mouse GALC protein facilitated the
release of the recombinant enzyme into the extracellular
medium.
To further analyze the recombinant GALC enzyme
released from the transduced cells into the extracellular
medium, a western blot analysis of concentrated cell culture
supernatants using a monoclonal antibody directed against
the myc epitope was carried out. As shown in Fig. 2, a single
band consistent with a molecular weight around 80 kDa was
detected in the culture medium harvested from transduced
cells including 293T and HeLa cells. The size of the myc-
tagged recombinant protein was close to that reported for
unmodified human GALC (Chen and Wenger 1993; Nagano
et al. 1998). Interestingly, the recombinant GALC-TMH
protein secreted by 293T and HeLa cells displayed a slightly
slower electrophoretic mobility compared with the recombi-
nant GALC-MH protein lacking a Tat-PTD. The same
mobility shift was observed with GALC-containing super-
natants collected from transduced COS-7 cells (data not
shown). The reason for this lower than expected electropho-
retic mobility of GALC-TMH relative to GALC-MH is not
clear.
Tat-PTD facilitated uptake of recombinant GALC by COS-7
cells, twitcher mouse FBs and by primary mouse neurons
To show that the recombinant GALC enzyme secreted from
transduced cells could be taken up by cells through M6PR-
mediated endocytosis, enzyme uptake assays were per-
formed. The results presented in Fig. 3 and Table 2 indicate
that COS-7 cells, Twi FBs and mouse cortical neurons were
capable of taking up GALC from the conditioned medium of
transduced COS-7 cells expressing GALC-MH or GALC-
TMH. Fig. 3 shows that GALC-MH and GALC-TMH in the
absence of M6P were taken up as efficiently as unmodified
GALC, indicating that modification of the C-terminus of
GALC did not affect the enzymes’ uptake. As shown in
Table 1 Distribution of recombinant galactocerebrosidase (GALC)









GALC-MH 41.2 ± 8.3 58.8 ± 8.3
GALC-TMH 27.5 ± 3.7 72.5 ± 3.7
GALC activities in cell extracts and cell culture supernatants of COS-7
cells expressing GALC-MH or GALC-TMH. Activities were determined
5 days after the cells were plated. The data shown are from four
independent experiments and displayed as mean values ± SD.
Endogenous GALC activity in transduced COS-7 cells amounted to
3% of that observed with the recombinant enzyme. GALC activity re-
leased is presented as daily GALC activity released into the culture
medium.
Fig. 2 Western blot analysis of recombinant galactocerebrosidase
(GALC) proteins released from lentivirus-transduced 293T and HeLa
cells. Cell culture supernatants (200 lg aliquots) from lentivirus-
transduced 293T and HeLa cells were collected and concentrated.
Concentrated proteins were analyzed by western blotting using a
monoclonal anti-myc antibody. Control: medium from untransduced
cells. Protein molecular weight markers are indicated.
Fig. 3 Uptake of recombinant galactocerebrosidase (GALC) bearing a
Tat-protein transduction domain (PTD) in the absence and presence
of mannose-6-phosphate (M6P). Conditioned media from COS-7 cells
expressing GALC-MH or GALC-TMH were added to COS-7 cells.
Media were left on cells for 24 h in the presence or absence of
5 mmol/L M6P as indicated. The cells were analyzed for intracellular
GALC activity. The values shown represent GALC units per mg of cell
extract. They were obtained from triplicate samples and are expressed
as mean values ± SD.
 2007 The Authors
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Fig. 3 and Table 2, uptake of recombinant GALC-MH was
largely blocked (67% for COS-7 cells, 77% for Twi FBs, and
up to 68% for primary neurons) in the presence of an excess
of M6P indicating that uptake was mostly mediated by
M6PR-mediated internalization. Uptake of GALC bearing a
Tat-PTD (GALC-TMH) was only partially inhibited by M6P
(35% in COS-7 cells and in Twi FBs and up to 17% in mouse
neurons). Taken together, these results provide evidence that
the recombinant GALC enzyme maintained the features of
the native GALC enzyme and that the Tat-PTD motif
facilitated M6PR-independent GALC uptake.
Localization of Tat-PTD-modified GALC protein and
Lamp-1 in twitcher mouse FBs
To assess the effects of the myc epitope and the Tat-PTD on
the subcellular distribution of GALC, the intracellular
location of the recombinant GALC-TMH protein in trans-
duced cells was analyzed by antibody staining using anti-
myc antibody and an antibody directed against the Lamp-1.
The confocal images shown in Fig. 4 indicate that the
punctate staining observed after incubation with monoclonal
anti-myc antibody followed by Alexa 488-labeled secondary
antibody overlapped in part with that of Lamp-1 indicating
that at least some of the Tat-PTD-modified GALC enzyme
was associated with lysosomes. To better resolve the
subcellular proximity and potential cross-over of myc-tagged
GALC and Lamp-1, a deconvolution analysis was per-
formed. Careful examination of optical sectioning throughout
the z-axis revealed that even though the majority of the myc
label would apparently yield a negative Pearson’s correlation
with respect to Lamp-1, a generous amount of signal was in
close proximity to the lysosomal compartments (data not
shown).
Correction of galactosylceramide accumulation in twitcher
mouse FBs after transduction using lentiviral vectors
encoding GALC-TMH or following GALC-TMH uptake
To show that GALC-TMH retained its enzymatic function
in vivo, the degradation of galactosylceramide in Twi FBs
following transduction using lentiviral vectors encoding
GALC-TMH was analyzed. FBs were loaded with BO-
DIPY-GalCer, a fluorescent analog of galactosylceramide










of M6P % Inhibition
GALC-MH COS-7 17.62 ± 1.53 5.9 ± 0.59 66.97 ± 5.67
GALC-TMH COS-7 26.35 ± 2.37 18.19 ± 3.34 34.60 ± 11.82
GALC-MH Twi FBs 11.44 ± 2.14 2.61 ± 1.18 77.19 ± 4.51
GALC-TMH Twi FBs 12.55 ± 1.22 8.22 ± 2.30 35.03 ± 12.91
GALC-MH Mouse neurons 43.60 14.1 67.64
GALC-MH Mouse neurons 203.17 76.22 62.49
GALC-TMH Mouse neurons 21.40 17.87 16.50
GALC-TMH Mouse neurons 132.88 111.54 16.06
Conditioned media from COS-7 cells expressing GALC-MH or GALC-TMH were added to cells.
Media were left on cells for 24 h in the presence or absence of 5 mmol/L mannose-6-phosphate
(M6P) as indicated. The cells were analyzed for intracellular GALC activity. The values for COS-7
cells and Twi FBs were obtained from triplicate samples and are expressed as mean values ± SD.
For mouse neurons, two independent sets of experiments are shown. The percentage of inhibition
of GALC uptake was calculated by comparing the uptake of GALC activity from the conditioned
medium in the presence of M6P to that in the absence of M6P. GALC activities are displayed as
GALC units per mg of protein.
Fig. 4 Confocal analysis of galactocerebrosidase (GALC) and lyso-
somal-associated protein-1 (Lamp-1) in Twi fibroblasts (FBs)
expressing GALC-MH or GALC-TMH. GALC-MH and GALC-TMH-
transduced Twi FBs (upper and center panels) and untransduced
(control) Twi FBs (lower panel) were stained using anti-myc (green)
and anti-Lamp-1 (red) antibody as described in Experimental proce-
dures. Cell nuclei were stained using DAPI.
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(Marks and Pagano 2002). The distribution and accumulation
of BODIPY-GalCer in FBs from affected mice (Twi FBs),
wild type mice (WT FBs) and FBs from affected mice
transduced with lentiviral vectors encoding GALC-TMH
(Twi FBs + GALC-TMH) were compared (Fig. 5a). In WT
FBs, BODIPY-GalCer was cleared, mediated by the endog-
enous GALC enzyme. However, residual fluorescence was
detected in perinuclear structures. In Twi FBs, there was
heavy accumulation of unhydrolyzed BODIPY-GalCer all
over the cells, presumably because of the lack of GALC
activity. The distribution of BODIPY-GalCer in Twi FBs
expressing GALC-TMH was similar to that seen in WT FBs,
indicating that Twi FBs expressing GALC-TMH rapidly
cleared BODIPY-GalCer (Fig. 5a). When Twi FBs were
incubated with conditioned medium containing GALC-
TMH, Twi FBs were also able to clear BODIPY-GalCer
(Fig. 5b, right panel), while Twi FBs incubated with control
medium lacking GALC did not (Fig. 5b, middle panel),
indicating that clearing was mediated by the exogenously
added GALC. To provide more direct evidence for GALC
uptake, Twi FBs were incubated with conditioned medium
containing GALC-TMH and then stained using polyclonal
anti-GALC antibodies (Lee et al. 2005b, 2007). The results
presented in Fig. 6 show that the staining pattern following
incubation with the anti-GALC antibody overlapped at least
in part with that obtained with the anti-Lamp-1 antibody.
This indicates that following uptake, recombinant GALC
was associated at least in part with lysosomes.
Discussion
Enzyme replacement therapy was first proposed as a
therapeutic strategy for LSDs soon after the enzymatic
defects were elucidated in the human sphingolipid storage
disorders Gaucher disease and Niemann-Pick disease (Brady
1966). Currently, ERT is a treatment option for Gaucher
disease type I, Fabry disease, and MPS I, and clinical
(a)
(b)
Fig. 5 Hydrolysis of BODIPY-GalCer in Twi fibroblasts (FBs) over-
expressing galactocerebrosidase (GALC)-TMH or following uptake of
GALC-TMH. (a) Mouse FBs were incubated with 5 lmol/L BODIPY-
GalCer. After back-exchange with buffer containing fatty acid-free
bovine serum albumin (BSA), images were taken using a fluorescence
microscope. Left panel, Twi FBs; Center panel, FBs derived from
normal mice; Right panel, Twi FBs over-expressing GALC-TMH. The
GALC-specific activities measured in these cells were 0.49, 3.06, and
33.20 GALC units per mg of protein, respectively. (b) Twi FBs were
incubated with conditioned medium for 24 h. Cells were then washed
and incubated with BODIPY-GalCer. Left panel, untreated Twi FBs;
Center panel, FBs incubated with conditioned medium from control
293 cells; Right panel, Twi FBs exposed to conditioned medium from
293 cells over-expressing GALC-TMH. The GALC-specific activities
used for uptake were as follows: Left panel: GALC activity undetect-
able; Middle panel: 0.3 GALC units per mL; Right panel: 20.2 GALC
units per mL.
Fig. 6 Confocal analysis of galactocerebrosidase (GALC) and lyso-
somal-associated protein-1 (Lamp-1) in Twi fibroblasts (FBs) following
uptake of GALC-TMH. Twi FBs were exposed to conditioned medium
from 293 cells over-expressing GALC-TMH (top panel). The bottom
panel shows Twi FBs incubated with conditioned medium from control
293 cells. Twenty-eight hours later, cells were stained with anti-GALC
(green) and anti-Lamp-1 (red) antibody as described in Experimental
procedures. Cell nuclei were stained using DAPI.
 2007 The Authors
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investigations are underway for Pompe disease, MPS II, and
MPS VI (Desnick and Schuchman 2002). This approach is
based on the fact that lysosomal enzymes contain oligosac-
charide residues (e.g. mannose and/or M6P) that bind to
cellular receptors (e.g. mannose or M6PR), leading to
internalization of the enzymes by clathrin-mediated endocy-
tosis and subsequent trafficking to lysosomes (Desnick and
Schuchman 2002). Inadequate glycosylation of recombinant
enzymes and/or lack of appropriate receptors in LSD target
cells are obstacles that may affect enzyme delivery and the
efficacy of ERT.
Alternative strategies aimed at improving enzyme uptake
were described recently. These focus on chimeric enzymes
containing alternative targeting moieties including a peptide
derived from insulin-like growth factor II (LeBowitz et al.
2004), the receptor-associated protein targeting the low-
density lipoprotein receptor (Prince et al. 2004), or the
tetanus toxin C fragment (Jiang et al. 2005). However,
chimeric enzymes often exhibit diminished activity. Also, the
M6PR and low-density lipoprotein receptor family receptors
are internalized via clathrin-mediated pathways, which are
defective in some lysosomal enzyme-deficient cells (Dhami
and Schuchman 2004). Other strategies have focused on
chimeric enzymes involving PTDs including the HIV Tat-
PTD (Xia et al. 2001; Elliger et al. 2002; Lee et al. 2005a).
Schwarze et al. (1999) were the first to show that
denatured proteins bearing the Tat-PTD, as large as E. coli
b-galactosidase, could translocate across membranes and
even enter the brain following intraperitoneal injection
involving a mechanism known as protein transduc-
tion(Schwarze and Dowdy 2000). However, these results
are difficult to apply to mammalian lysosomal enzymes in
general, in part because hydrophilic oligosaccharide side
chains on the glycosylated acid hydrolases prevent proper
refolding and assembly of multimeric enzymes following
denaturation. Thus, their translocation across cell membranes
may be impeded (Orii et al. 2005). Results reported by Xia
et al. (2001), Elliger et al. (2002), and Orii et al. (2005)
showed that the Tat-PTD affected secretion, uptake and
biodistribution of native GUS. Furthermore, the Tat motif
significantly increased the distribution of GUS secreted from
transduced cells after intravenous or direct brain injection in
mice with recombinant adenovirus vectors (Xia et al. 2001;
Elliger et al. 2002; Alisky et al. 2006).
It is evident from our studies that mouse GALC can also
be modified to bear a Tat-PTD without diminishing its
function. Our results indicate that the recombinant GALC
protein containing a Tat-PTD domain not only maintained
the features of the native GALC protein including enzymatic
function in vitro and in situ and intracellular transport, but it
also displayed more efficient intercellular uptake via a
M6PR-independent pathway.
It was previously shown that BODIPY-lactosylceramide
and BODIPY-GalCer are taken up by cells and transferred to
the Golgi compartment (Chen et al. 1999). Interestingly, in
several LSDs including Krabbe disease, these fluorescent
lipids were found to accumulate in late endosomes/lyso-
somes (Chen et al. 1999; Puri et al. 1999). Our results show
that clearance of accumulated BODIPY-GalCer in Twi FBs
did occur following expression (Fig. 5a) or uptake (Fig. 5b)
of GALC-TMH by such cells. The residual perinuclear
fluorescence seen in WT FBs (Fig. 5a, middle panel) may
indicate non-hydrolyzed BODIPY-GalCer residing in a
vesicular compartment to which endogenous GALC does
not have access. Interestingly, in Twi FBs expressing GALC,
this perinuclear fluorescence was not as pronounced possibly
because GALC levels in such cells were at least 10 times
higher compared with those in WT FBs.
The mechanism(s) affecting Tat-PTD-mediated uptake and
distribution of recombinant proteins need to be clarified.
Several lines of evidence suggest that the PTDs only mediate
cell surface adherence, a property shared with many other
positively charged macromolecules. The cell surface adher-
ence results in endocytosis and accumulation of proteins in
endosomes. As eight of the 11 amino acid residues of the Tat-
PTD are positively charged, Tat may bind negatively charged
phospholipids of cell membranes and glycosaminoglycans on
the cell surface which may mediate adsorptive endocytosis of
Tat-modified proteins (Lundberg et al. 2003). This view is
supported by recent findings obtained with GUS-Tat fusion
proteins (Orii et al. 2005). Preliminary studies indicate that
the uptake of GALC-TMH was blocked in the presence of
heparin (Zhang, unpublished). This supports the view that
GALC-TMH may also be taken up by adsorptive endocy-
tosis.
In conclusion, in this study we show that Tat-modified
GALC retains enzymatic activity, is efficiently secreted from
cells, and is taken up by other cells via M6PR-dependent and
independent mechanisms. We expect these findings to
ultimately lead to improved therapies for GLD.
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